ADC Therapeutics reports Q3 2026 results, restructuring extends cash runway into 2029Nov 9Quarterly updateADC Therapeutics SAloncastuximab tesirine
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
BMS: Reblozyl label supplement approved; GLORY CAR-T trial and BMS-986485 Phase 1 postedOct 22Weekly roundup, 4 itemsBristol Myers Squibbliso-celUpdated
ADC Therapeutics restructures finances with $86.6 million private placementOct 13FinancingADC Therapeutics SA
Genentech lists Phase Ib KRAS G12D trial; Roche-sponsored DLBCL study shows updateOct 9Weekly roundup, 9 itemsalectinibcisplatinUpdated
Roche's glofitamab Phase 2 trial in untreated DLBCL posts results after primary completionAug 18Trial updateglofitamabprednisone
ADC Therapeutics reweighs ZYNLONTA path after FDA raises LOTIS-5 safety concernsAug 13Quarterly updateADC Therapeutics SAloncastuximab tesirine
Arvinas reports Q2 2026 results after first-ever FDA approval of a PROTAC drugAug 4Quarterly updateArvinas Inc.
BMS trials post results across lung cancer, sarcoma, myelofibrosis; new stroke study opensJul 17Weekly roundup, 5 itemsBristol Myers Squibblisocabtagene maraleucel